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Cancer is one of the leading causes of morbidity and mortality worldwide. Since the identification of cancer stem cells
(CSCs), plenty of studies have suggested that this small subpopulation of cancer cells with tumour-initiating capability
is the core origin of the tumorigenesis and intra-tumour heterogeneity. CSCs are also thought to be responsible for
the conventional therapy-resistance and tumour relapse, thus being one of the most promising therapeutic targets.
Targeting CSCs directly
Promote proliferation of CSCs from quiescent state
Attack the CSC niche
Inhibit the transitions between CSCs and non-CSCs 
Stochastic model
CSCs model
Dynamic model
The CSCs model postulates the existence of biologically and functionally distinct classes of cells in a
tumour. CSCs are in the apex of the hierarchy and undergo asymmetrically to give rise to more CSCs and
to non-CSCs that will form the bulk of the tumour. In this case, only a subset of cells present in a low
frequency in the tumour are able to initiate tumour growth.
Tumours are initiated by a CSCs (CSC1), but during the progression of the disease different clones of
CSCs (CSC2, CSC3) can appear due to stochastic mutations either in CSCs existing clones or even in
differentiated-non-tumorigenic cells which provide them with reprogramming capacities. The more
aggressive CSC clones will become dominant and drive tumour growth.
According to stochastic model, all tumour cells are biologically equivalent and the multiple cell
populations forming the tumour are a result of genetic mutations which appear by a stochastic
manner. The progression of tumour follows the clonal evolution, in which some clones have an
increased survival advantage and outcompete the other tumour cells.
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• Cancers whose incidence is higher
depending on the age.
• Differentiated cells lifespan prevents
the accumulation of enough mutations
to become neoplastic.
• CSCs, as proliferating cells, shouldn’t
be resistant to conventional therapies.
• Recent studies demonstrate that CSCs
may not necessary to be in a low
frequency in tumours.
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CSCs have been suggested to require their CSC niche to maintain stem cell properties and to favour the
reprogramming process by which non-CSCs are converted into CSCs.
Angiogenesis has key roles in cancer
initiation and progression. vascular
endothelial growth factor A (VEGFA)
secreted in the vascular niche helps
maintenance of glioblastoma CSCs
In leukaemia brain, pancreatic
and ER-positive breast cancer,
hypoxia inducible factor (HIF)
induces the dedifferentiation of
non-CSCs into CSCs.
Macrophages recruited into the
tumour tissue secrete TFG-ß which:
- Supress immunosurvillance.
- Stimulates EMT.
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Ab-based therapeutics
Aptamer-mediated therapy 
Small molecules
Nucleic acid-based therapies
CRISPR/Cas9
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• Stemloids dormancy
• Altered metabolism
• High capacity for DNA repair
• Cell plasticity
• Microenvironmental factors
• Reactive oxygen species
• ATP binding cassette (ABC)-
related transporters
• Noisy gene expression
1. To stablish CSCs characteristics.
2. To understand CSCs role in tumour growth and heterogeneity by the evolution of the concept in the last 20 years.
3. To determine the possible therapeutic strategies targeting CSCs to prevent tumour relapse.
• CSCs, similarly as normal stem cells, possess the ability to divide asymmetrically giving rise to daughter cells that will differentiate into
the neoplastic cells forming the bulk of the tumour as well as daughter cells that will remain as CSCs.
• The dynamic model of tumour heterogeneity explains that some tumours may not follow a clear hierarchy and that CSCs might not
necessarily have to be rare.
• Although the elimination of CSCs offers an exciting potential to cure cancer, it may be not enough as many cancers show dynamic
stemness. Therefore, it is necessary to combine therapy approaches to first eliminate CSCs populations that already reside in the
tumour and to secondly control a variety of reprogramming mechanisms either by blocking cell-signalling pathways or niche-specific
signals.
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CSCs share common features with normal stem cells: 
Undifferentiated 
state
Self-renewal 
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1. Normal stem cells.
2. Differentiated cell that express reprogramming factors.
3. Differentiated cell that suffers epithelial-to-mesenchymal 
transition (EMT).
There are 3 possible origins for CSCs: 
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